ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
CNY 9.27
(1.64%)
CNY 9.27
(1.64%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 654.64 Million CNY | -23.4% |
| 2022 | 854.64 Million CNY | 9.26% |
| 2021 | 782.22 Million CNY | -15.7% |
| 2020 | 927.9 Million CNY | 6.73% |
| 2019 | 869.42 Million CNY | 54.03% |
| 2018 | 564.47 Million CNY | 3.11% |
| 2017 | 547.41 Million CNY | 14.59% |
| 2016 | 477.73 Million CNY | 9.59% |
| 2015 | 435.93 Million CNY | 21.71% |
| 2014 | 358.17 Million CNY | 10.82% |
| 2013 | 323.21 Million CNY | 83.65% |
| 2012 | 175.99 Million CNY | 44.98% |
| 2011 | 121.39 Million CNY | -7.51% |
| 2010 | 131.25 Million CNY | -7.51% |
| 2009 | 141.9 Million CNY | 20.82% |
| 2008 | 117.45 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 674.68 Million CNY | -0.49% |
| 2024 Q1 | 672.85 Million CNY | 2.78% |
| 2024 Q2 | 677.98 Million CNY | 0.76% |
| 2023 Q2 | 960.43 Million CNY | 5.33% |
| 2023 Q1 | 911.85 Million CNY | 6.69% |
| 2023 Q4 | 654.64 Million CNY | -11.63% |
| 2023 FY | 654.64 Million CNY | -23.4% |
| 2023 Q3 | 740.76 Million CNY | -22.87% |
| 2022 Q4 | 854.64 Million CNY | 0.77% |
| 2022 FY | 854.64 Million CNY | 9.26% |
| 2022 Q2 | 759.33 Million CNY | -3.53% |
| 2022 Q3 | 848.13 Million CNY | 11.69% |
| 2022 Q1 | 787.14 Million CNY | 0.63% |
| 2021 Q3 | 814.85 Million CNY | -4.0% |
| 2021 Q4 | 782.22 Million CNY | -4.0% |
| 2021 Q2 | 848.83 Million CNY | -3.88% |
| 2021 FY | 782.22 Million CNY | -15.7% |
| 2021 Q1 | 883.14 Million CNY | -4.82% |
| 2020 Q3 | 878.69 Million CNY | -7.15% |
| 2020 Q1 | 920.35 Million CNY | 5.86% |
| 2020 Q2 | 946.38 Million CNY | 2.83% |
| 2020 Q4 | 927.9 Million CNY | 5.6% |
| 2020 FY | 927.9 Million CNY | 6.73% |
| 2019 Q1 | 511.21 Million CNY | -9.43% |
| 2019 FY | 869.42 Million CNY | 54.03% |
| 2019 Q2 | 457.41 Million CNY | -10.52% |
| 2019 Q4 | 869.42 Million CNY | 45.62% |
| 2019 Q3 | 597.04 Million CNY | 30.52% |
| 2018 Q3 | 536.95 Million CNY | -1.65% |
| 2018 FY | 564.47 Million CNY | 3.11% |
| 2018 Q2 | 545.97 Million CNY | 9.5% |
| 2018 Q4 | 564.47 Million CNY | 5.12% |
| 2018 Q1 | 498.59 Million CNY | -8.92% |
| 2017 Q4 | 547.41 Million CNY | -11.65% |
| 2017 FY | 547.41 Million CNY | 14.59% |
| 2017 Q1 | 499.22 Million CNY | 4.5% |
| 2017 Q2 | 561.17 Million CNY | 12.41% |
| 2017 Q3 | 619.59 Million CNY | 10.41% |
| 2016 Q1 | 463.28 Million CNY | 6.28% |
| 2016 FY | 477.73 Million CNY | 9.59% |
| 2016 Q4 | 477.73 Million CNY | 5.98% |
| 2016 Q3 | 450.79 Million CNY | -14.22% |
| 2016 Q2 | 525.49 Million CNY | 13.43% |
| 2015 Q2 | 472.7 Million CNY | 54.95% |
| 2015 Q3 | 325.81 Million CNY | -31.07% |
| 2015 Q4 | 435.93 Million CNY | 33.8% |
| 2015 FY | 435.93 Million CNY | 21.71% |
| 2015 Q1 | 305.06 Million CNY | -14.83% |
| 2014 Q3 | 263.05 Million CNY | 4.84% |
| 2014 Q2 | 250.92 Million CNY | -15.67% |
| 2014 Q1 | 297.55 Million CNY | -7.94% |
| 2014 FY | 358.17 Million CNY | 10.82% |
| 2014 Q4 | 358.17 Million CNY | 36.16% |
| 2013 Q1 | 125.67 Million CNY | -28.59% |
| 2013 Q3 | 215.91 Million CNY | 99.9% |
| 2013 Q4 | 323.21 Million CNY | 49.7% |
| 2013 FY | 323.21 Million CNY | 83.65% |
| 2013 Q2 | 108 Million CNY | -14.06% |
| 2012 Q3 | 172.91 Million CNY | 6.64% |
| 2012 FY | 175.99 Million CNY | 44.98% |
| 2012 Q2 | 162.14 Million CNY | 24.47% |
| 2012 Q1 | 130.26 Million CNY | 7.31% |
| 2012 Q4 | 175.99 Million CNY | 1.78% |
| 2011 Q4 | 121.39 Million CNY | 11.91% |
| 2011 Q2 | 130.07 Million CNY | 0.0% |
| 2011 Q3 | 108.47 Million CNY | -16.61% |
| 2011 FY | 121.39 Million CNY | -7.51% |
| 2010 FY | 131.25 Million CNY | -7.51% |
| 2010 Q4 | 131.25 Million CNY | 0.0% |
| 2009 FY | 141.9 Million CNY | 20.82% |
| 2008 FY | 117.45 Million CNY | 0.0% |